Reporting from the ESMO Congress 2021, Rocio Garcia-Carbonero summarises the interesting results presented in the NETs track including the phase III SPINET study testing lanreotide autogel/depot in patients with advanced lung NETs, response and PFS results from the AXINET study testing axitinib plus octreotide LAR in patients with grade 1-2 extrapancreatic NETs, and the GCO-001 NIPINEC of nivolumab+ipilimumab in pre-treated patients with advanced refractory pulmonary or GEP poorly differentiated NECs, designed to explore the efficacy of immunotherapy in this setting.
1096O - Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): results from the phase 3 SPINET study - Dr Dieter Horsch, DE
1097O - The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs - Prof Rocio Garcia-Carbonero, ES
LBA41 - Nivolumab (nivo) ± Ipilimumab (ipi) in pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (GCO-001 NIPINEC) - Prof Thomas Walter, FR
This video is part of a sponsored track. The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.